Company / Total Debt
Axsome Therapeutics, Inc. Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$117.7M
FY2025
5-year range
$49.1M / $180.7M
FY2021-FY2025
Trend
-34.8%
vs FY2024
Sector context
#54 of 83
Health Care
What the data says
At $118M, Axsome Therapeutics, Inc.'s total debt ranks #30 of 83 in the Health Care sector. Improved from $178M to $118M over the past 2 years.
Based on SEC 10-K filings.
$118M in FY2025 with a 5-year CAGR of +19.5%.
Improved from $178M to $118M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +7.7%
- 5-Year CAGR
- +19.5%
- 10-Year CAGR
- -
Sector benchmark
#30 of 83 in Health CareTop 35% of 83This company $117.7M Sector average $6.2B
▼
-98.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +19.5%, indicating consistent growth.
- In FY2025, total debt decreased 34.8% year-over-year.
- Ranks #54 out of 83 companies in the Health Care sector.
- Peak total debt was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $117.7M | -34.8% |
| FY2024 | $180.7M | +1.5% |
| FY2023 | $178.1M | +88.9% |
| FY2022 | $94.3M | +92.0% |
| FY2021 | $49.1M | +1.6% |
| FY2020 | $48.3M | +178.8% |
| FY2019 | $17.3M | +378.9% |
| FY2018 | $3.6M | -45.7% |
| FY2017 | $6.7M | -29.6% |
| FY2016 | $9.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026